Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Fiorenzo Santoleri, Elena Ranucci, Gaetano La Barba, Irene Colasanto, Matilde Scaldaferri, Francesco Cattel, Francesca Federici, Chiara Rossi, Katiuscia Di Biagio, Anna Rita Scortechini, Felice Musicco, Giancarlo Torquati, Angela Frazzetto, Antonietta Vozza, Caterina de Rosa, Rosaria Lanzillo, Maria Monteverde, Luigia Luciano, Fabrizio Pane, Arianna Pasquazi, Maria Grazia Celeste, Maria Cantonetti, Luca Franceschini, Manuela Rizzo & Alberto Costantini. (2021) Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life. Current Medical Research and Opinion 37:3, pages 477-481.
Read now
Read now
B. Douglas Smith, Jun Liu, Dominick Latremouille-Viau, Annie Guerin, Daniel Fernandez & Lei Chen. (2016) Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Current Medical Research and Opinion 32:5, pages 817-827.
Read now
Read now
Fausto R. Loberiza$suffix/text()$suffix/text(), Andrew C. Cannon, Anthony J. Cannon & Philip J. Bierman. (2014) Insights on practice variations in the management of lymphoma and leukemia. Leukemia & Lymphoma 55:11, pages 2449-2456.
Read now
Read now
Annie Guérin, Lei Chen, Katherine Dea, Eric Q. Wu & Stuart L. Goldberg. (2014) Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. Journal of Medical Economics 17:2, pages 89-98.
Read now
Read now
James D. Griffin, Annie Guerin, Lei Chen, Alexander R. Macalalad, Jiayuan Luo, Raluca Ionescu-Ittu & Eric Qiong Wu. (2013) Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis. Current Medical Research and Opinion 29:6, pages 623-631.
Read now
Read now
Articles from other publishers (17)
Justin Gatwood, Ankur Dashputre, Abhijeet Rajpurohit, Katie Gatwood, Emily Mackler, Leah Wallace, Karen Farris, Amna Rizvi-Toner & Joel Farley. (2023) Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions. Journal of Oncology Pharmacy Practice, pages 107815522311719.
Crossref
Crossref
Nazish Matti, Claire Delon, Marie-Christine Rybarczyk-Vigouret, Gul Majid Khan, Morgane Beck & Bruno Michel. (2020) Adherence to oral anticancer chemotherapies and estimation of the economic burden associated with unused medicines. International Journal of Clinical Pharmacy 42:5, pages 1311-1318.
Crossref
Crossref
Christel C. L. M. Boons, Lonneke Timmers, Jeroen J. W. M. Janssen, Peter E. Westerweel, Nicole M. A. Blijlevens, Willem M. Smit, Imke H. Bartelink, Janneke A. Wilschut, Eleonora L. Swart, N. Harry Hendrikse & Jacqueline G. Hugtenburg. (2020) Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. European Journal of Clinical Pharmacology 76:9, pages 1213-1226.
Crossref
Crossref
Yasuhiro Maeda, Atsushi Okamoto, Kenta Yamamoto, Go Eguchi & Yoshitaka Kanai. (2019) Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase. Reports 2:4, pages 25.
Crossref
Crossref
Alan Rodrigues Andrade, Daniel da Silva Leitão, Igor Penha Paz, Talitta Ribeiro Evangelista, Vanessa Joia de Mello & Moisés Hamoy. (2019) Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon. Hematology, Transfusion and Cell Therapy 41:2, pages 106-113.
Crossref
Crossref
Anna Rychter, Piotr Jerzmanowski, Adam Hołub, Zofia Specht-Szwoch, Violetta Kalinowska, Urszula Tęgowska, Ilona Seferyńska, Agnieszka Kołkowska-Leśniak, Ewa Lech-Marańda & Joanna Góra-Tybor. (2017) Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Medical Oncology 34:6.
Crossref
Crossref
Tomasz Sacha, Joanna Góra-Tybor, Ewa Wąsak-Szulkowska, Sławomira Kyrcz-Krzemień, Ewa Mędraś, Rafał Becht, Grażyna Bober, Aneta Kotowska, Joanna Wącław & Andrzej Hellmann. (2017) Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study. Clinical Lymphoma Myeloma and Leukemia 17:5, pages 283-295.
Crossref
Crossref
Yasuhiro Maeda, Atsushi Okamoto, Shin-ichiro Kawaguchi, Akiko Konishi, Kenta Yamamoto, Go Eguchi, Yoshitaka Kanai & Terufumi Yamaguchi. (2017) Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors. Acta Haematologica 138:3, pages 140-142.
Crossref
Crossref
Joseph A. Greer, Nicole Amoyal, Lauren Nisotel, Joel N. Fishbein, James MacDonald, Jamie Stagl, Inga Lennes, Jennifer S. Temel, Steven A. Safren & William F. Pirl. (2016) A Systematic Review of Adherence to Oral Antineoplastic Therapies. The Oncologist 21:3, pages 354-376.
Crossref
Crossref
Alix E. Hall, Chris Paul, Jamie Bryant, Marita C. Lynagh, Philip Rowlings, Anoop Enjeti & Hannah Small. (2016) To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Critical Reviews in Oncology/Hematology 97, pages 247-262.
Crossref
Crossref
Marie Barillet, Virginie Prevost, Florence Joly & Bénédicte Clarisse. (2015) Oral antineoplastic agents: how do we care about adherence?. British Journal of Clinical Pharmacology 80:6, pages 1289-1302.
Crossref
Crossref
Lei Chen & Eric Q. Wu. (2015) Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. Journal of Managed Care & Specialty Pharmacy 21:11, pages 1088-1089.
Crossref
Crossref
Henry J. Henk, Mabel Woloj, Mark Shapiro & Jennifer Whiteley. (2015) Real-world Analysis of Tyrosine Kinase Inhibitor Treatment Patterns Among Patients With Chronic Myeloid Leukemia in the United States. Clinical Therapeutics 37:1, pages 124-133.
Crossref
Crossref
Françoise Huguet. (2014) ENESTnd trial: a Phase III study comparing nilotinib with imatinib as front-line therapy of early chronic-phase chronic myeloid leukemia. International Journal of Hematologic Oncology 3:2, pages 117-129.
Crossref
Crossref
David Cella, Cindy J. Nowinski & Olga Frankfurt. (2014) The Impact of Symptom Burden on Patient Quality of Life in Chronic Myeloid Leukemia. Oncology 87:3, pages 133-147.
Crossref
Crossref
I. Sari, S. Korkmaz, M. Sencan, I. Kiki, E.N. Tiftik, H. Kaya, C. Demir, A. Unal, F. Altuntas & O. Ilhan. (2013) The clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study. Journal of Geriatric Oncology 4, pages S58.
Crossref
Crossref
Winson Y. Cheung. (2013) Difficult to Swallow: Issues Affecting Optimal Adherence to Oral Anticancer Agents. American Society of Clinical Oncology Educational Book:33, pages 265-270.
Crossref
Crossref